Compare Delta Air Lines, Inc. (DAL) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Danaher Corporation — how do they compare? Delta Air Lines, Inc. trades at $81.16 (market cap $54.02B), while Danaher Corporation trades at $220.55 (market cap $152.87B). The key difference: Danaher Corporation is far larger — about 2.8× Delta Air Lines, Inc.'s market cap, and Delta Air Lines, Inc. pays the higher dividend (1.05%). Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Danaher Corporation for 69 Days on average.
| DAL | DHR | |
|---|---|---|
Market Cap | $54.02B | $152.87B |
Volume | 9,632,845 | 5,228,698 |
Sector | Industrials | Health |
52-Week High | $93.66 | $242.05 |
52-Week Low | $55.65 | $161.91 |
Typical Hold Time | 97 Days | 69 Days |
Enterprise Value | $69.34B | $175.08B |
Dividend Yield | 1.05% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $80.49, down 2.99% on the day, as technical indicators signal bearish momentum with the stock testing support near $80. Fundamentally, the company shows solid profitability with a 5.78% net margin and 20.12% ROE, though Q3 2026 earnings missed expectations. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's in-flight internet instead of Starlink.
The investment outlook remains positive with strong analyst support (82% buy ratings) and a $103.36 consensus price target offering 28% upside. Key risks include fuel cost volatility, rising crew expenses, and competitive threats to premium customer retention. Cash flow trends show improvement with net positive flows since 2024.
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
